A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61P 27/00 (2006.01)
Patent
CA 2621086
Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
L'invention concerne des méthodes et des médicaments destinés au traitement de la maladie inflammatoire oculaire auto-immune. Ces méthodes consistent à administrer des agents agissant comme des antagonistes de l'activité de l'IL-17 et/ou de l'IL-23.
Caspi Rachel
Cua Daniel J.
Kastelein Robert A.
Luger Dror
Silver Phyllis
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Schering Corporation
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services
The Government Of The United States Of America As Represented By
LandOfFree
Use of il-23 and il-17 antagonists to treat autoimmune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of il-23 and il-17 antagonists to treat autoimmune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of il-23 and il-17 antagonists to treat autoimmune... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1378410